Access to medications that reduce the risk of cancer in the NHS

Access to chemoprevention in the NHS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN14292000

Enrollment

1000

Registered

2016-03-21

Start date

2016-03-28

Completion date

Unknown

Last updated

2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prescribing behaviour Cancer

Interventions

GPs will be randomised to read one of four vignettes describing a 45 year old patient at increased risk of breast cancer. The GPs are told to imagine the patient has consulted them and they have been

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. General practitioner (or GP specialist trainee) 2. Based in the UK

Exclusion criteria

Exclusion criteria: Not a General Practitioner

Design outcomes

Primary

Measure	Time frame
The main effects of: 1. Risk level 2. First prescriber on willingness to prescribe tamoxifen. This will be measured immediately after reading the vignette using the item: 'Would you be willing to write the prescription for [patient name]?', 'Not at all willing', 'probably not willing' 'probably willing' 'definitely willing'.	—

Secondary

Measure	Time frame
Current secondary outcome measures as of 15/09/2017: All outcomes will be measured immediately after the GP has read the vignette. 1. Interaction between risk level and first prescriber on willingness to prescribe tamoxifen 2. Willingness to prescribe within pre-defined respondent groups: 2.1. Males vs. female GPs 2.2. GP specialist trainees vs. GP partners vs. Salaried GPs 2.3. Special interest in cancer/preventive medicine/family history/genetics vs. none of these 3. Wanting to speak with a colleague before writing the prescription ('Would you want to speak with anyone else before you decided whether to write this prescription?' 'yes' 'no') 4. Comfort in discussing the possible benefits and harms of tamoxifen ('How comfortable would you feel discussing the possible benefits and harms of tamoxifen with [patient name]?' 'very uncomfortable' 'quite uncomfortable' 'quite comfortable' 'very comfortable' 5. Comfort in managing the care of the patient ('If [patient name] started taking tamoxifen, how comfortable would you feel managing her care for the duration of the prescription?' 'very uncomfortable' 'quite uncomfortable' 'quite comfortable' 'very comfortable') 6. Factors considered during the decision-making process: ('How much do you agree or disagree that the following factors affected your decision of whether or not to write a prescription for [patient name]?' 'Strongly disagree' 'disagree' 'agree' 'strongly agree' 6.1. Evidence for the benefits of the drug 6.2. The evidence for the harms of the drug 6.3. Prescribing ‘off-label’ 6.4. The first prescription being made by a family history clinician 6.5. The first prescription being made by the GP 6.6.The financial costs of tamoxifen 6.7. Patient risk level 6.8. Patient’s interest in taking tamoxifen 6.9. Patient’s awareness of the possible harms and benefits 6.10. GP’s confidence in knowledge of tamoxifen 6.11. Patient’s support from the genetics clinician 6.12. The attitudes of the GP’s colleagues who ar	—

Measure

Time frame

Current secondary outcome measures as of 15/09/2017: All outcomes will be measured immediately after the GP has read the vignette. 1. Interaction between risk level and first prescriber on willingness to prescribe tamoxifen 2. Willingness to prescribe within pre-defined respondent groups: 2.1. Males vs. female GPs 2.2. GP specialist trainees vs. GP partners vs. Salaried GPs 2.3. Special interest in cancer/preventive medicine/family history/genetics vs. none of these 3. Wanting to speak with a colleague before writing the prescription ('Would you want to speak with anyone else before you decided whether to write this prescription?' 'yes' 'no') 4. Comfort in discussing the possible benefits and harms of tamoxifen ('How comfortable would you feel discussing the possible benefits and harms of tamoxifen with [patient name]?' 'very uncomfortable' 'quite uncomfortable' 'quite comfortable' 'very comfortable' 5. Comfort in managing the care of the patient ('If [patient name] started taking tamoxifen, how comfortable would you feel managing her care for the duration of the prescription?' 'very uncomfortable' 'quite uncomfortable' 'quite comfortable' 'very comfortable') 6. Factors considered during the decision-making process: ('How much do you agree or disagree that the following factors affected your decision of whether or not to write a prescription for [patient name]?' 'Strongly disagree' 'disagree' 'agree' 'strongly agree' 6.1. Evidence for the benefits of the drug 6.2. The evidence for the harms of the drug 6.3. Prescribing ‘off-label’ 6.4. The first prescription being made by a family history clinician 6.5. The first prescription being made by the GP 6.6.The financial costs of tamoxifen 6.7. Patient risk level 6.8. Patient’s interest in taking tamoxifen 6.9. Patient’s awareness of the possible harms and benefits 6.10. GP’s confidence in knowledge of tamoxifen 6.11. Patient’s support from the genetics clinician 6.12. The attitudes of the GP’s colleagues who ar

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026